These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 38056618)

  • 1. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
    Melander SA; Kayed A; Andreassen KV; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2024 Jan; 962():176215. PubMed ID: 38056618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists.
    Zhang X; Cai Y; Yao Z; Chi H; Li Y; Shi J; Zhou Z; Sun L
    Peptides; 2023 Mar; 161():170948. PubMed ID: 36646385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.
    Kayed A; Melander SA; Khan S; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2023 Mar; 384(3):406-416. PubMed ID: 36418115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
    Bhat VK; Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.
    Ding WX; Wang HY; Peng LJ; Zhang F; Yuan S; Zhao LH
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12423-12436. PubMed ID: 33336763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model.
    Bosch R; Petrone M; Arends R; Vicini P; Sijbrands EJG; Hoefman S; Snelder N
    Br J Pharmacol; 2024 Jun; 181(12):1874-1885. PubMed ID: 38403793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects.
    Zhao L; Wang B; Wang L; Zhao X; Chen Z; Sun L
    Org Biomol Chem; 2019 Sep; 17(33):7760-7771. PubMed ID: 31389463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A GLP-1/glucagon (GCG)/CCK
    Zhao S; Yan Z; Du Y; Li Z; Tang C; Jing L; Sun L; Yang Q; Tang X; Yuan Y; Han J; Jiang N
    Br J Pharmacol; 2022 Sep; 179(17):4360-4377. PubMed ID: 35484823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice.
    Ma T; Huo S; Xu B; Li F; Wang P; Liu Y; Lei H
    Eur J Med Chem; 2020 Oct; 203():112496. PubMed ID: 32682196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
    Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
    Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent.
    Liu C; Li C; Cai X; Zou Y; Mo J; Chen B; Cai Y; Han T; Huang W; Qian H; Zhang W
    Bioorg Chem; 2021 Jan; 106():104492. PubMed ID: 33268008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
    Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
    Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
    Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
    Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
    Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
    Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice.
    Yang PY; Zou H; Amso Z; Lee C; Huang D; Woods AK; Nguyen-Tran VTB; Schultz PG; Shen W
    Bioconjug Chem; 2020 Apr; 31(4):1167-1176. PubMed ID: 32243137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.
    Kosinski JR; Hubert J; Carrington PE; Chicchi GG; Mu J; Miller C; Cao J; Bianchi E; Pessi A; Sinharoy R; Marsh DJ; Pocai A
    Obesity (Silver Spring); 2012 Aug; 20(8):1566-71. PubMed ID: 22421924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties.
    Cai X; Li C; Zhou J; Dai Y; Avraham Y; Sun L; Liu C; Tong J; Wang Y; Bi X; He L; Huang W; Qian H
    Bioorg Chem; 2020 Jan; 95():103538. PubMed ID: 31901754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.